Integrating Skin Cancer–Related Technologies into Clinical Practice - 07/09/17

Doi : 10.1016/j.det.2017.06.018

Richard R. Winkelmann, DO ^a, Aaron S. Farberg, MD ^b, Alex M. Glazer, MD ^c, Clay J. Cockerell, MD ^d, Arthur J. Sober, MD ^e, Daniel M. Siegel, MD, MS ^f, Sancy A. Leachman, MD, PhD ^g, Whitney A. High, MD, JD ^h, Orit Markowitz, MD ⁱ, Brian Berman, MD, PhD ^j, David M. Pariser, MD ^k, Gary Goldenberg, MD ^l, Theodore Rosen, MD ^m, Darrell S. Rigel, MD, MS ^n,^⁎
^a Department of Dermatology, OhioHealth, 75 Hospital Drive STE 250, Athens, OH 4570, USA
^b Department of Dermatology, Icahn School of Medicine at Mt. Sinai, 1425 Madison Avenue, Floor 2, New York, NY 10029, USA
^c National Society for Cutaneous Medicine, 35 East 35th Street #208, New York, NY 10016, USA
^d Department of Dermatology, The University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard. 4th Floor, Suite 100, Dallas, TX 75390, USA
^e Department of Dermatology, Harvard Medical School, 50 Staniford Street, 2nd Floor, Boston, MA 02114, USA
^f Department of Dermatology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
^g Department of Dermatology, OHSU Knight Cancer Institute, Oregon Health & Science University, 3303 S.W. Bond Avenue, Portland, OR 97239, USA
^h Department of Dermatology & Pathology, University of Colorado School of Medicine, 12635 E Montview Boulevard, Bioscience Park, Suite 160, Aurora, CO 80045, USA
ⁱ Department of Dermatology, Mount Sinai Medical Center, 5 E 98th Street, FL 5, New York, NY 10029, USA
^j Department of Dermatology, University of Miami Miller School of Medicine, 2925 Aventura Boulevard, Suite 205, Aventura, FL 33180, USA
^k Department of Dermatology, Eastern Virginia Medical School, 6160 Kempsville Circle, Suite 200A, Norfolk, VA 23502, USA
^l Department of Dermatology, Mount Sinai Medical Center, 5 E 98th Street, FL 5, New York, NY 10029, USA
^m Department of Dermatology, Baylor College of Medicine, 1977 Butler Street, Suite E6.200, Houston, Texas 77030, USA
ⁿ Department of Dermatology, NYU School of Medicine, 35 East 35th Street #208, New York, NY 10016, USA

^∗Corresponding author.

Résumé

Early diagnosis and treatment of melanoma improve survival. New technologies are emerging that may augment the diagnosis, assessment, and management of melanoma but penetrance into everyday practice is low. In the current health care climate, greater emphasis will be placed on the incorporation of technology for clinically suspicious pigmented lesions to facilitate better, more cost-effective management.

Le texte complet de cet article est disponible en PDF.

Keywords : Skin cancer, Technology, Diagnosis, Prognosis, Management, Melanoma, Dysplastic nevi, Genetic testing

Plan

Clinically High Suspicion Pigmented Skin Lesions

Clinically Intermediate Suspicion Pigmented Skin Lesions

Clinically Low Suspicion Pigmented Skin Lesions

Summary

Relevant Conflicts of Interest: Dr R.R. Winkelmann: fellowship funded in part by grant from Strata Skin Sciences Inc; Dr A.S. Farberg: fellowship funded in part by grant from Strata Skin Sciences Inc, consultant to Castle Biosciences Inc; Dr A.M. Glazer: participated in a research fellowship which was partially funded by Castle Biosciences Inc; Dr A.J. Sober: P.I for phase 4 Strata Skin Sciences Inc Trial; Dr C.J. Cockerell: consultant to Strata Skin Sciences Inc, Castle Biosciences Inc, and Myriad Genetics; Dr D.M. Siegel: member, Board of Directors, Caliber I.D.; Clinical Advisory Board, Michelson Diagnostics, LTD, and Advisory Board attendee for Castle Biosciences Inc; Dr S.A. Leachman: Myriad Genetics Laboratory Medical & Scientific Advisory Board member; Dr W.A. High: None; Dr O. Markowitz: consultant for 3-Gen, Michelson Diagnostics Ltd, and Strata Skin Sciences Inc; Dr B. Berman: None; Dr D.M. Pariser: Advisory Board attendee for Castle Biosciences Inc; Dr G. Goldenberg: consultant to Strata Skin Sciences Inc; Dr T. Rosen: Advisory Board attendee for Castle Biosciences Inc; and Dr D.S. Rigel: served as chief medical advisor to Strata Skin Sciences Inc, consultant to Castle Biosciences Inc.